Preventive effects of cyclohexenonic long-chain fatty alcohol on diabetic cystopathy in the rat.
In this study, we investigated the preventive effect of n-hexacosanol on diabetes-induced bladder dysfunction in the rat. Diabetes was induced in 8-week-old male Sprague-Dawley rats by administering an injection of streptozotocin (50 mg/kg, i.p.). The rats were randomly divided into 4 groups (age-matched control rats, diabetic rats without treatment with n-hexacosanol, and diabetic rats treated with n-hexacosanol (2 and 8 mg/kg, i.p. every day)) and maintained for 4 weeks. The serum glucose and serum insulin levels were determined, and the functions of bladder were estimated by voiding behavior, cystometric, and functional studies to carbachol and KCl. Furthermore, we examined possible diabetic induced histological changes in these rats. Treatment with n-hexacosanol did not alter diabetic status including body mass, bladder mass, and serum glucose and serum insulin levels, but significantly improved the maximum contraction pressure of the detrusor and residual urine volume in cystometric studies and Emax values to carbachol in functional studies in a dose-dependent manner. Diabetes induced bladder smooth muscle hypertrophy, which tended to be ameliorated by treatment with n-hexacosanol in a dose-dependent manner. Treatment with n-hexacosanol did not alter the diabetic status, but significantly improved diabetic cystopathy in a dose-dependent manner.
Suzuki
Hiroto
H
Meiji Dairies Corporation, Pharmaceuticals Department, Tokyo, Japan.
Saito
Motoaki
M
Kinoshita
Yukako
Y
Satoh
Itaru
I
Kono
Tomoharu
T
ShinBori
Chiko
C
Anastasios
Sylakos
S
Yamada
Masashi
M
Satoh
Keisuke
K
D000818:Animals; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use; D053138:Cyclohexenes; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D005233:Fatty Alcohols / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001745:Urinary Bladder Diseases / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D014554:Urination / Q000187:drug effects / Q000502:physiology
D003510:Cyclohexanes; D053138:Cyclohexenes; D005233:Fatty Alcohols; C052568:cyclohexene; C051942:1-hexacosanol